SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will release its financial results for the quarter ended September 30, 2007 on Tuesday, November 13, 2007 after the close of the U.S. financial markets.
CryoCor will also hold a Web cast and conference call at 5:00 p.m. ET / 2:00 p.m. PT on November 13, 2007. Management will discuss the financial results, recent regulatory and clinical activities, its intellectual property strategy and the status of its commercial launch of the Company’s Cardiac Cryoablation System for the treatment of right atrial flutter.
The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company’s corporate Web site at www.cryocor.com.
After the live Web cast, the call will remain available on CryoCor’s Web site for at least 30 days following presentation. In addition, a telephonic replay of the call will be available. The replay dial-in numbers are 1-877-660-6853 for domestic callers 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 260426.
About CryoCor
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company’s product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company’s website at http://www.cryocor.com
gtibbitts@cryocor.com nlaudico@theruthgroup.comzkubow@theruthgroup.comjrando@theruthgroup.com
CONTACT: Gregory J. Tibbitts, Chief Financial Officer of CryoCor, Inc.,
+1-858-909-2200, gtibbitts@cryocor.com; or Investors: Nick Laudico,
+1-646-536-7030, nlaudico@theruthgroup.com, or Zack Kubow, +1-646-536-7020,
zkubow@theruthgroup.com, or Media: Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, all of The Ruth Group for CryoCor, Inc.
Web site: http://www.cryocor.com/
